The idea that led to the site-agnostic indication for Keytruda (pembrolizumab) came from the academic oncologists, who ended up defining the biologic mechanism of activity of this class of drugs.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
